IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v610y2022i7931d10.1038_s41586-022-05068-3.html
   My bibliography  Save this article

Genomics to select treatment for patients with metastatic breast cancer

Author

Listed:
  • Fabrice Andre

    (Gustave Roussy
    INSERM U981, Gustave Roussy
    Gustave Roussy
    Université Paris Saclay)

  • Thomas Filleron

    (Institut Claudius Regaud, IUCT oncopole)

  • Maud Kamal

    (Institut Curie)

  • Fernanda Mosele

    (INSERM U981, Gustave Roussy)

  • Monica Arnedos

    (Gustave Roussy)

  • Florence Dalenc

    (Institut Claudius-Regaud IUCT oncopole and University of Paul Sabatier)

  • Marie-Paule Sablin

    (Institut Curie
    Institut Curie)

  • Mario Campone

    (Institut de Cancérologie de l’Ouest – René Gauducheau, Saint Herblain, University of Angers)

  • Hervé Bonnefoi

    (Institut Bergonié INSERM U1218 and Université of Bordeaux)

  • Claudia Lefeuvre-Plesse

    (Centre Eugène Marquis)

  • William Jacot

    (Institut du Cancer de Montpellier, Institut de Recherche en Cancérologie de Montpellier INSERM U1194 and Montpellier University)

  • Florence Coussy

    (Institut Curie)

  • Jean-Marc Ferrero

    (Centre Antoine Lacassagne, University Côte d’Azur)

  • George Emile

    (Centre François Baclesse)

  • Marie-Ange Mouret-Reynier

    (Centre Jean Perrin)

  • Jean-Christophe Thery

    (Centre Hennri Becquerel, University of Medicine of Rouen)

  • Nicolas Isambert

    (Centre Georges François Leclerc)

  • Alice Mege

    (Institut Sainte Catherine)

  • Philippe Barthelemy

    (Institut de Cancérologie Strasbourg Europe)

  • Benoit You

    (Institut de Cancérologie des Hospices Civils de Lyon, Université Claude Bernard Lyon 1)

  • Nawale Hajjaji

    (Centre Oscar Lambret INSERM U1192 PRISM Laboratory and University of Lille)

  • Ludovic Lacroix

    (Gustave Roussy)

  • Etienne Rouleau

    (Gustave Roussy)

  • Alicia Tran-Dien

    (INSERM U981, Gustave Roussy
    Gustave Roussy
    Gustave Roussy)

  • Sandrine Boyault

    (Centre Léon Bérard)

  • Valery Attignon

    (Centre Léon Bérard)

  • Pierre Gestraud

    (PSL Research University, Mines Paris Tech, INSERM U900)

  • Nicolas Servant

    (PSL Research University, Mines Paris Tech, INSERM U900)

  • Christophe Tourneau

    (Institut Curie)

  • Linda Larbi Cherif

    (Institut Curie)

  • Isabelle Soubeyran

    (Institut Bergonié)

  • Filippo Montemurro

    (FPO-IRCCS)

  • Alain Morel

    (Institut de Cancérologie de l’Ouest – Centre Paul Papin)

  • Amelie Lusque

    (Institut Claudius Regaud, IUCT oncopole)

  • Marta Jimenez

    (Unicancer)

  • Alexandra Jacquet

    (Unicancer)

  • Anthony Gonçalves

    (Institut Paoli-Calmettes)

  • Thomas Bachelot

    (Centre Léon Bérard)

  • Ivan Bieche

    (Institut Curie, INSERM U1016, Université Paris Cité)

Abstract

Cancer progression is driven in part by genomic alterations1. The genomic characterization of cancers has shown interpatient heterogeneity regarding driver alterations2, leading to the concept that generation of genomic profiling in patients with cancer could allow the selection of effective therapies3,4. Although DNA sequencing has been implemented in practice, it remains unclear how to use its results. A total of 1,462 patients with HER2-non-overexpressing metastatic breast cancer were enroled to receive genomic profiling in the SAFIR02-BREAST trial. Two hundred and thirty-eight of these patients were randomized in two trials (nos. NCT02299999 and NCT03386162) comparing the efficacy of maintenance treatment5 with a targeted therapy matched to genomic alteration. Targeted therapies matched to genomics improves progression-free survival when genomic alterations are classified as level I/II according to the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)6 (adjusted hazards ratio (HR): 0.41, 90% confidence interval (CI): 0.27–0.61, P

Suggested Citation

  • Fabrice Andre & Thomas Filleron & Maud Kamal & Fernanda Mosele & Monica Arnedos & Florence Dalenc & Marie-Paule Sablin & Mario Campone & Hervé Bonnefoi & Claudia Lefeuvre-Plesse & William Jacot & Flor, 2022. "Genomics to select treatment for patients with metastatic breast cancer," Nature, Nature, vol. 610(7931), pages 343-348, October.
    • Handle: RePEc:nat:nature:v:610:y:2022:i:7931:d:10.1038_s41586-022-05068-3
    DOI: 10.1038/s41586-022-05068-3
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41586-022-05068-3
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/s41586-022-05068-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:610:y:2022:i:7931:d:10.1038_s41586-022-05068-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.